Mark E. Robson

58.4k total citations · 10 hit papers
412 papers, 19.5k citations indexed

About

Mark E. Robson is a scholar working on Genetics, Oncology and Cancer Research. According to data from OpenAlex, Mark E. Robson has authored 412 papers receiving a total of 19.5k indexed citations (citations by other indexed papers that have themselves been cited), including 222 papers in Genetics, 161 papers in Oncology and 130 papers in Cancer Research. Recurrent topics in Mark E. Robson's work include BRCA gene mutations in cancer (206 papers), Cancer Genomics and Diagnostics (91 papers) and PARP inhibition in cancer therapy (74 papers). Mark E. Robson is often cited by papers focused on BRCA gene mutations in cancer (206 papers), Cancer Genomics and Diagnostics (91 papers) and PARP inhibition in cancer therapy (74 papers). Mark E. Robson collaborates with scholars based in United States, United Kingdom and Canada. Mark E. Robson's co-authors include Kenneth Offit, Susan M. Domchek, Jaya M. Satagopan, Nadine Tung, Judy E. Garber, Larry Norton, Jeffrey N. Weitzel, Jeff Boyd, Binghe Xu and Elżbieta Senkus and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Mark E. Robson

383 papers receiving 19.1k citations

Hit Papers

Olaparib for Metastatic B... 2002 2026 2010 2018 2017 2010 2002 2015 2004 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
    2017 2.2k citations Mark E. Robson, Susan M. Domchek et al. profile →
  2. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
    2010 1.3k citations Mark E. Robson, Judy E. Garber et al. profile →
  3. Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2Mutation
    2002 891 citations Noah D. Kauff, Mark E. Robson et al. profile →
  4. Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk
    2015 579 citations Marc Tischkowitz, D. Gareth Evans et al. profile →
  5. A note on competing risks in survival data analysis
    2004 559 citations Mark E. Robson et al. profile →
  6. Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes
    2017 521 citations Mark E. Robson, Marc Ladanyi et al. profile →
  7. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility
    2015 512 citations Mark E. Robson, Susan M. Domchek et al. Journal of Clinical Oncology profile →
  8. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
    2019 497 citations Mark E. Robson, Nadine Tung et al. Annals of Oncology profile →
  9. Genome doubling shapes the evolution and prognosis of advanced cancers
    2018 343 citations Pedram Razavi, Mark E. Robson et al. profile →
  10. Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline
    2024 67 citations Payal D. Shah, Marc Tischkowitz et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mark E. Robson 9.1k 8.0k 6.0k 5.9k 3.4k 412 19.5k
Susan M. Domchek 8.8k 1.0× 10.2k 1.3× 4.9k 0.8× 6.0k 1.0× 3.0k 0.9× 334 19.7k
Olufunmilayo I. Olopade 7.4k 0.8× 7.5k 0.9× 6.3k 1.0× 7.1k 1.2× 2.0k 0.6× 420 20.0k
Rosalind A. Eeles 7.0k 0.8× 5.7k 0.7× 3.9k 0.6× 5.8k 1.0× 4.7k 1.4× 361 17.7k
Paul D.P. Pharoah 6.1k 0.7× 6.7k 0.8× 4.8k 0.8× 7.3k 1.2× 2.7k 0.8× 340 19.9k
Kenneth Offit 8.3k 0.9× 5.2k 0.7× 4.1k 0.7× 4.9k 0.8× 1.2k 0.4× 311 16.6k
Jan G.M. Klijn 5.8k 0.6× 6.1k 0.8× 6.0k 1.0× 6.7k 1.1× 1.6k 0.5× 148 16.8k
Douglas F. Easton 16.9k 1.9× 8.8k 1.1× 8.0k 1.3× 12.8k 2.2× 3.4k 1.0× 358 33.9k
Timothy R. Rebbeck 5.6k 0.6× 3.7k 0.5× 2.7k 0.4× 3.0k 0.5× 2.0k 0.6× 257 12.7k
Karen H. Lu 3.9k 0.4× 6.8k 0.9× 4.8k 0.8× 7.4k 1.3× 1.8k 0.5× 427 21.6k
David Cameron 3.5k 0.4× 13.6k 1.7× 7.0k 1.2× 5.6k 0.9× 4.8k 1.4× 533 23.8k

Countries citing papers authored by Mark E. Robson

Since Specialization
Citations

This map shows the geographic impact of Mark E. Robson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Robson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Robson more than expected).

Fields of papers citing papers by Mark E. Robson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Robson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Robson. The network helps show where Mark E. Robson may publish in the future.

Co-authorship network of co-authors of Mark E. Robson

This figure shows the co-authorship network connecting the top 25 collaborators of Mark E. Robson. A scholar is included among the top collaborators of Mark E. Robson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark E. Robson. Mark E. Robson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ferraro, Emanuela, Andrea V. Barrio, Daniel J. Kelly, et al.. (2024). Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab. npj Breast Cancer. 10(1). 96–96.
2.
3.
Rowlands, Charlie F, Judith Balmañà, Susan M. Domchek, et al.. (2024). Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing. Annals of Oncology. 35(10). 892–901. 7 indexed citations
4.
Schmid, Peter, Heather L. McArthur, Baojun Xu, et al.. (2024). LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial. Annals of Oncology. 35. S1212–S1213. 5 indexed citations
5.
6.
Amir, Eitan, Mark E. Robson, Nour Abuhadra, et al.. (2024). The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review. Critical Reviews in Oncology/Hematology. 202. 104455–104455.
7.
8.
Ferraro, Emanuela, Atif J. Khan, George Plitas, et al.. (2024). Abstract PO3-04-07: Characterization of response to first-line chemotherapy, trastuzumab, and pertuzumab among patients with de novo metastatic HER2-positive breast cancer. Cancer Research. 84(9_Supplement). PO3–4. 1 indexed citations
9.
Moiso, Enrico, Emanuela Ferraro, Luc Cabel, et al.. (2024). Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2- metastatic breast cancer: A machine learning approach.. Journal of Clinical Oncology. 42(16_suppl). 1074–1074. 1 indexed citations
10.
11.
Chow, Angela, Seo-Young Han, Courtney Coker, et al.. (2024). FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer. EMBO Molecular Medicine. 16(8). 1957–1980. 2 indexed citations
12.
13.
Daly, Bobby, Jessie C. Holland, Chasity Burrows Walters, et al.. (2021). Oncology Patients' Perspectives on Remote Patient Monitoring for COVID-19. JCO Oncology Practice. 17(9). e1278–e1285. 23 indexed citations
14.
Pareja, Fresia, Lorenzo Ferrando, Simon Lee, et al.. (2020). The genomic landscape of metastatic histologic special types of invasive breast cancer. npj Breast Cancer. 6(1). 53–53. 18 indexed citations
15.
Turner, Nicholas C., Melinda L. Telli, Hope S. Rugo, et al.. (2018). A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clinical Cancer Research. 25(9). 2717–2724. 88 indexed citations
16.
Robson, Mark E.. (2016). An ethnographic study of the introduction of internal supervisors to an internal coaching scheme. SHILAP Revista de lepidopterología. 1 indexed citations
17.
Girard, Nicolas, Emil Lou, Christopher G. Azzoli, et al.. (2010). Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report. Clinical Cancer Research. 16(2). 755–763. 70 indexed citations
18.
Kirchhoff, Tomas, Zhang-qun Chen, Bert Gold, et al.. (2009). The 6q22.33 Locus and Breast Cancer Susceptibility. Cancer Epidemiology Biomarkers & Prevention. 18(9). 2468–2475. 15 indexed citations
19.
Kauff, Noah D., Susan M. Domchek, Tara M. Friebel, et al.. (2008). Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study. Journal of Clinical Oncology. 26(8). 1331–1337. 381 indexed citations
20.
Robson, Mark E., Murray H. Seltzer, Teresa Gilewski, et al.. (1997). Prevalence of Recurring BRCA Mutations Among Ashkenazi Jewish Women with Breast Cancer. Genetic Testing. 1(1). 47–51. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susan M. Domchek Breakdown of academic impact, for papers by Olufunmilayo I. Olopade Breakdown of academic impact, for papers by Rosalind A. Eeles Breakdown of academic impact, for papers by Paul D.P. Pharoah Breakdown of academic impact, for papers by Kenneth Offit Breakdown of academic impact, for papers by Jan G.M. Klijn Breakdown of academic impact, for papers by Douglas F. Easton Breakdown of academic impact, for papers by Timothy R. Rebbeck Breakdown of academic impact, for papers by Karen H. Lu Breakdown of academic impact, for papers by David Cameron
Rankless by CCL
2026